Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-β1/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Translational Therapeutic Opportunities
Youcef M. Rustum · 2026
Read Repurposing Seleno-L-Methionine as a Pleiotropic Immunomodulatory Agent to Overcome TGF-β1/HIF-Driven Immune Evasion in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Translational Therapeutic Opportunities by Youcef M. Rustum (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13565954.txt.
Description
Youcef Rustum argues, in twenty twenty-six, for repurposing a selenium compound to fight immune evasion in clear cell kidney cancer. This cancer often shrugs off immune checkpoint drugs, and cell therapies struggle too. A gene loss common in it keeps two pathways, TGF-beta and HIF, switched on. Together they drive blood vessel growth, metabolic rewiring, and immune escape. They raise suppressive signals that keep T cells out and exhaust them. The compound, seleno-L-methionine, at drug-level doses, suppressed both pathways in preclinical studies.
Its active metabolite also lowered the downstream suppressive signals, at safe, reachable doses. Prior evidence shows it boosts chemotherapy and vessel-targeted drugs. The review gathers signs that it may also restore immune attack, opening a translational path for this hard-to-treat cancer.
Catalog record
| CREATOR | Youcef M. Rustum |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |